Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
stocks
Nvidia: Back in business in China; Raising fair value estimate
stocks
Our top ASX picks in every sector
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,816.40 | 58.90 | -0.66% |
CAC 40 | 7,766.21 | 41.96 | -0.54% |
DAX 40 | 24,060.29 | 100.35 | -0.42% |
Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
FTSE 100 | 8,938.32 | 59.74 | -0.66% |
HKSE | 24,621.26 | 31.14 | 0.13% |
NASDAQ | 20,677.80 | 37.47 | 0.18% |
Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
S&P 500 | 6,243.76 | 24.80 | -0.40% |
S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
SSE Composite Index | 3,501.90 | 3.10 | -0.09% |